From a public health perspective, the short-term cost of boosting GLP-1 drug coverage could lead to long-term cost savings associated with emergent and routine care for chronic conditions like cardiovascular disease, liver disease, heart failure, and depression, all of which are comorbid with obesity
Retatrutide is currently investigational and not commercially FDA-approved
As always, Ill be answering your questions in the comments
They have not undergone the rigorous pre-market review process that FDA-approved medications complete
Inhibition of ROS generation ROS is mainly generated directly in the mitochondrial oxidative respiratory chain, NADPH oxidase, and partially in peroxisomes, endoplasmic reticulum misfolded proteins, and Fenton reaction